💊 Drugs A-Z 🧬 Targets 🛠 Tools 📚 Guides
All Drugs Drug Classes Therapeutic Areas Side Effects
Guides Glossary Timeline
Comparisons Drug Journeys Drug Families
🇺🇸 English
Same Drug Class

Enalapril vs Ramipril

Overview

Enalapril and ramipril are both prodrug ACE inhibitors with landmark trial evidence. Enalapril is the reference standard for HFrEF (CONSENSUS, SOLVD); ramipril is the reference standard for broad cardiovascular protection in high-risk patients (HOPE).

Mechanism of Action

Both require ester hydrolysis to active diacids (enalaprilat, ramiprilat). Both inhibit ACE, reducing angiotensin II and aldosterone. Ramiprilat has slightly higher ACE affinity than enalaprilat.

Pharmacokinetics

Enalapril: bioavailability ~60%, enalaprilat half-life ~11 h. Ramipril: bioavailability ~60%, ramiprilat half-life ~13–17 h with tissue binding extending effective duration. Both are renally eliminated.

Clinical Evidence

CONSENSUS (1987) and SOLVD-Treatment (1991) with enalapril established the mortality benefit of ACEi in HFrEF. HOPE (2000) with ramipril extended the indication to high-risk patients without low EF. Both drugs are considered equivalent for most ACEi indications in guidelines.

Key Takeaways

  • Enalapril: landmark HFrEF trials (CONSENSUS, SOLVD)
  • Ramipril: landmark broad CV protection trial (HOPE)
  • Both prodrugs with similar PK and efficacy class effects

Verdict

Enalapril is typically preferred for HFrEF based on the historical CONSENSUS/SOLVD data. Ramipril is preferred for cardiovascular risk reduction in high-risk patients without overt HF. In practice, both are interchangeable for most ACEi indications per current ACC/AHA guidelines.